A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study

Cancer Investigation
Eric KrautOhio State University Phase II Reseeearch Consortium Study

Abstract

This multicenter phase II trial evaluated the efficacy and toxicity of the topoisomerase I inhibitor topotecan (TPT, 9-dimethylaminomethyl-10-hydroxycamptothecin) in patients with refractory or relapsing non-Hodgkin's lymphoma. Thirty-two patients with previously treated non-Hodgkin's lymphoma were accrued in this study from June 1992 to June 1997. Patients were eligible if they had measurable disease and had received two or less chemotherapy treatments for indolent lymphoma or no more than one treatment for aggressive lymphoma. Nineteen patients with aggressive lymphoma including seven with transformed indolent disease and 11 patients with indolent disease were treated. Two additional patients had both indolent and aggressive lymphoma in the bone marrow and lymph nodes at entrance into the study. Topotecan was administered as a 30-min infusion at a dose of 1.25 mg/m2 for five days and repeated at three week intervals. Thirty-two patients were evaluable for toxicity and 29 patients were evaluable for response. There were five objective responses including two complete remissions and three partial remissions (17%; CI 4-30%). Four of the five responders had aggressive disease and had been responsive to prior chemotherapy. The dur...Continue Reading

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyS H Kaufmann
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R OhnoM Oguro
Dec 17, 1989·Biochimica Et Biophysica Acta·P D'Arpa, L F Liu
Mar 1, 1989·Controlled Clinical Trials·R Simon
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyS H Kaufmann
Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H SchillerD Johnson
Jan 1, 1996·Annual Review of Biochemistry·J C Wang
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J CreemersW W Ten Bokkel Huinink
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W H WilsonP Elwood

❮ Previous
Next ❯

Citations

Sep 13, 2006·Leukemia & Lymphoma·Sonali M SmithUNKNOWN Cancer and Leukemia Group B
Oct 29, 2009·Leukemia & Lymphoma·Mark Kirschbaum
Oct 4, 2002·Hematological Oncology
Jul 24, 2008·Cancer Chemotherapy and Pharmacology·Nancy L BartlettUNKNOWN Cancer and Leukemia Group B
Jun 25, 2010·Investigational New Drugs·Derek S SernaEric H Kraut
Apr 11, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L FischerA Korfel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

© 2022 Meta ULC. All rights reserved